Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (DE:J7Z)
FRANKFURT:J7Z
RESEARCH TOOLSreports
Holding DE:J7Z?
Track your performance easily
J7Z Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€92.40 - €131.25
Previous Close€96.38
Volume10.00
Average Volume (3M)29.00
Market Cap
€5.98B
Enterprise Value€9.96B
Total Cash (Recent Filing)$1.36B
Total Debt (Recent Filing)$5.77B
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Nov 05, 2024EPS Estimate
€4.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding61,753,510
10 Day Avg. Volume0
30 Day Avg. Volume29
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.59
Price to Sales (P/S)1.72
Price to Cash Flow (P/CF)5.10
P/FCF Ratio5.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit2.93
Enterprise Value/Ebitda12.16
Forecast
1Y Price Target
€156.54Price Target Upside62.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Jazz Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
EarningsJazz reported 2Q with revenue above consensus (in line with us), demonstrated spending discipline yielding operating income above the Street, and the bottom line further boosted by low tax.
Financial PerformanceStrong quarter of revenue for Epidiolex, as 2Q24 sales of $247M were 22% higher than 2Q23.
Strategic InitiativesJazz Pharmaceuticals is expanding its sales force and nurse educator program to support growth in idiopathic hypersomnia.
Bears Say
Market CompetitionThe narcolepsy market is more mature and has seen less growth overall due to competition from authorized generics and branded fixed dose products.
Product PerformanceExpectations for the oncology business were lowered as adoption of Rylaze in the AYA market has taken longer than expected.
Revenue Guidance2024 oncology revenue guidance was lowered to $1.10 to $1.15B (from $1.12 to $1.22B).
---
J7Z FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was €92.40 and its highest was €131.25 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Currently, no data Available
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Nov 05, 2024 which is in 39 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Jul 31, 2024. The company reported €4.771 earnings per share for the quarter, beating the consensus estimate of €4.431 by €0.34.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is €4.97.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 61,753,510 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of €4.771 in its last earnings report, beating expectations of €4.431. Following the earnings report the stock price went up 4.275%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 147M.
---
Jazz Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€156.54 (62.42% Upside)
€156.54 (62.42% Upside)
Blogger Sentiment
Bullish
DE:J7Z Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $152.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.59%
12-Months-Change
Fundamentals
Return on Equity
10.84%
Trailing 12-Months
Asset Growth
0.90%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
J7Z Company Deck
---
J7Z Earnings Call
Q2 2024
0:00 / 0:00
---
J7Z Stock 12 Month Forecast
Average Price Target
€156.54
▲(62.42% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Vertex Pharmaceuticals
―
Regeneron
―
Incyte
―
BioMarin Pharmaceutical
―
Best Analysts Covering J7Z
1 Year
1 Year Success Rate
13/24 ratings generated profit
1 Year Average Return
+3.00%
reiterated a buy rating 16 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +3.00% per trade.
---